Kim R. Tsuchimoto

Kim R. Tsuchimoto, listed as finance chief, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Monopar Therapeutics, Raptor Pharmaceutical Corp and Raptor Pharmaceuticals Corp. We count 71 filings; the first trade dates from 17 May 2007 and the latest from 4 November 2026.

In open-market terms, that means 1 purchase worth €2,332 on one side and 22 sales worth €1.4M on the other. The net balance comes to €1.4M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 19 share grants and 29 option exercises. Since January 2026: no purchases and 16 sales on the market.

Most recently, on 4 November 2026, the filings show an option exercise worth €32k in Monopar Therapeutics. The clock since the last published purchase (20 December 2019) now reads 2,515 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.